Table 2 Clinical characteristics of head and neck cancer patients from whom tumor tissue samples were collected for organoid establishment and experimentation.
Organoid ID | Age (y)/Sex | Tumor site | Stage group | Primary tumor stage | Nodal stage | Radiation therapy dose (Gy) | Chemotherapy | Follow-up |
|---|---|---|---|---|---|---|---|---|
HN-003 | 83/M | Oral cavity (floor of mouth) | IVA | T2 | N2b | 60 | None | Died 19 months post-treatment (cause unknown) |
HN-011 | 62/M | Larynx | IVA | T4a | N0 | 60 | Cisplatin | Alive; NED 34 months post-treatment |
HN-015 | 52/M | Larynx | IVB | T4a | N3b | 60 | Carboplatin | Died 15 months post-treatment (metastasis to lung versus new primary lung squamous cell carcinoma) |
HN-018 | 88/M | Skin (cheek) | II | ryT3 | N0 | 44 | None | Died 4 months after surgery with local recurrence |
HN-029 | 78/F | Oral cavity (buccal) | IVB | T4b | N0 | 60 | Carboplatin | Alive; NED 24 months post-treatment |
